Minerva Neurosciences Inc (NERV) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.49 (+0.87%), Market cap $0.24B, 52-week low–high $1.38 ~ $8.07.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Financial statements, price targets, institutional (13F) holdings and related news for Minerva Neurosciences Inc are updated in real time on BlackAll Trade.
Minerva Neurosciences Inc trades at $3.49 (+0.87%). Real-time quotes and charts are available on BlackAll Trade.
Minerva Neurosciences Inc has a market cap of about $0.24B.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. It